Vitality Watch

Dossier clinicaltrials trial early 21-jul-2026
Small or early-phase human trial or pilot study

Advanced Hybrid Closed Loop System (AHCL) in Older Patients With Type 1 Diabetes Mellitus

Key claim: A 12-month randomized trial will test whether MiniMed 780G advanced hybrid closed-loop therapy versus continued MDI/CSII improves glucose indices, physical capacity, frailty and sarcopenia measures, quality of life, and cognition in older adults with type 1 diabetes.

Abstract

The trial is a randomized controlled, parallel group design study. Patients will be followed up during approximatively 12 months.

Patients will be randomized to either the MDI/CSII group which will continue their treatment as per routine procedures and the advanced Hybrid Closed Loop system (AHCL) group which will be connected to the Minimed 780G system. .

At the end of the 12 month study period, we will evaluate whether the AHCL system improved glucose indices in older individuals with Type 1 diabetes mellitus (T1DM) and assess whether the ACHL treatment improved physical capacity, frailty & sarcopenia indices as well as quality of life and cognitive functions.

Why this matters

A 12-month randomized trial will test whether MiniMed 780G advanced hybrid closed-loop therapy versus continued MDI/CSII improves glucose indices, physical capacity, frailty and sarcopenia measures, quality of life, and cognition in older adults with type 1 diabetes.

Source

Link

Briefing card

Advanced Hybrid Closed Loop System (AHCL) in Older Patients With Type 1 Diabetes Mellitus
Stage: trial early · clinicaltrials · 21-jul-2026

A 12-month randomized trial will test whether MiniMed 780G advanced hybrid closed-loop therapy versus continued MDI/CSII improves glucose indices, physical capacity, frailty and sarcopenia measures, quality of life, and cognition in older adults with type 1 diabetes.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT06236256

build build 880 · 2bcef25 · 2026-11-18